

# Merus

## Merus to Participate in a Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference

April 6, 2022

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- [Merus N.V.](#) (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclronics® and Triclronics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13 at 10:15-10:55 a.m. ET.

The webcast of the fireside chat will be contemporaneously available on the [Investors page](#) of the Company's website. The archived presentation will also be available there for a limited time after the event.

### About Merus

[Merus](#) is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as [Multiclronics®](#). Multiclronics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit [Merus' website](#), and [twitter](#).

### Investor and Media Inquiries:

Sherri Spear

Merus N.V.

VP Investor Relations and Corporate Communications

617-821-3246

[s.spear@merus.nl](mailto:s.spear@merus.nl)

Kathleen Farren

Merus N.V.

IR/Corp Comms

617-230-4165

[k.farren@merus.nl](mailto:k.farren@merus.nl)

# Merus